Mandana kazemi
Type 1 diabetes usually begins in childhood or adolescence but may start at any age and comprises only5 to 10 percent of all diabetes cases, however its prevalence continues to increase worldwide.Type 1diabetes (T1D) is defined as an autoimmune disorder caused by T-cell mediated degradation of theInsulin-producing pancreas and begins with a combination of genetic and environmental factors.Manysignaling pathways, including IL-17, are involved in autoimmune diseases. Interleukin-17 (IL-17) is a 32-kDa hemodymeric cytokine and is distributed everywhere but is apparently more abundant in thespleen and kidney.In addition to its invasion by HSV T lymphocytes, this cytokine secretes IL-6, IL-8,PGE2, MCP-1, G-CSF by fibroblast cells, keratinocytes, epithelial and endothelial cells.IL-17 has beenshown to be involved in the pathogenesis of hypertension, atherosclerosis and lipid differentiation, andthe role of IL-17 in glucose metabolism has been elucidated and six members of its family (IL-17A-F)have been identified.IL-17A is largely produced by activated memory T lymphocytes but stimulatesinnate immunity and host defense.IL-17A and IL-17F partially mobilize neutrophils through induction ofCXC granulopoiesis and chemotaxin as well as enhancing local survival. Evidence suggests that IL-17family members play an active role in cancer, inflammatory and autoimmune diseases.The aim of thisstudy was to select genes involved in IL17 pathway based on expression profiles obtained from microbialstudies from GEO database and evaluate their expression changes in order to introduce biomarkers fortype I diabetes mellitus.
